We welcome Emmanuel Blin as our new Chairman of the Board!

May 18, 2021

We are excited to announce that we have appointed Emmanuel Blin as Chairman of our Board of Directors.Emmanuel brings a wealth of knowledge and experience in the healthcare and pharma space through his 20+ year career at Bristol-Myers Squibb, where he also served as the Group’s Chief Strategy Officer, as well as his recent Board engagements, including his role as Chairman at Noona Healthcare.

Just like us, Emmanuel is also a mission-driven entrepreneur, working on his own social impact healthcare startup, Tech Care for All.

“I look forward to working with the team on their next stage of growth, as I am convinced Aignostics has the right setup to become successful on the global stage. A Charité spin-off with strong ties to university research and pharma, excellent access to multi-modal data, close collaboration with pathologists, an outstanding proprietary Explainable AI platform, first-class investors, and a strong team, are just a few of the factors that make Aignostics stand out in my view. I am also impressed by the traction this young team has already built up.”

“I definitely speak for the whole team and Board when I say we are thrilled to welcome Emmanuel. We think Emmanuel’s experience will be invaluable as we expand our work in building complex AI models for translational and clinical research with pharma and biotech partners; and also in charting a way towards the clinics with Companion Diagnostics, which we think will be a key enabler for the precision medicine approaches of tomorrow.”, says Viktor Matyas, CEO of Aignostics.

We wish Emmanuel a great start!

About Aignostics

Aignostics, a Berlin based company with offices in the US, is a digital pathology company dedicated to novel precision diagnostics through the use of a proprietary “Explainable AI” platform in pre-clinical and translational research and clinical trials. The use of such technology is expected to be crucial to implementation of AI-powered algorithms in routine diagnostics in order to verify (explain) the model’s decision outputs. Additionally, through its close alignment to Charité and TU Berlin amongst other collaborators, only Aignostics offers the combination of data access, sample testing and pathology expertise to develop digital pathology algorithms spanning multi-modal biomarker assay detection systems such as H&E, IHC and mIF, amongst others.


Aignostics GmbH
Viktor Matyas, CEO

Email: info@aignostics.com